Development of a new bioassay for adiponectin agonist action

This project will pair together a academic Canadian research group with a pharmaceutical company who have developed a novel therapeutic (ALY688) to the stage that it will soon begin phase 1 clinical trials for the treatment of metabolic disease, such as diabetes. Since the success, and safety, of clinical trials requires accurate dosing of the new drug there is a need to develop a way to monitor the amount required to safely induce beneficial effects on the body. At the moment there is no assay which easily allows analysis of ALY688 action.

Developing methods to isolate regulatory innate lymphocytes

Enhancing tissue homeostasis and immune tolerance mechanisms is pivotal for the development of new therapeutic approaches for transplantation and autoimmunity. This proposal is focused on harnessing newly discovered types of lymphocytes that regulates immune responses in cell-based immunotherapies. We are developing methods to isolate and expand these newly identified regulatory lymphocytes and are assessing their ability to prevent immune-mediated tissue damage. The goal of these studies being to use these cells in immune-based therapies for transplantation.

Defining and Targeting Autoimmune Liver Disease

The liver is the largest solid organ in the body and is critical for metabolic and immune functions, however huge gaps still exist in our basic knowledge of the human liver. Due to challenges in obtaining human liver tissue and the fragility of liver specimens, little is known about the cells that make up the human liver and its immune microenvironment: much of our current understanding is derived from studies in animal models.

Defining and Targeting Autoimmune Liver Disease

The liver is the largest solid organ in the body and is critical for metabolic and immune functions, however huge gaps still exist in our basic knowledge of the human liver. Due to challenges in obtaining human liver tissue and the fragility of liver specimens, little is known about the cells that make up the human liver and its immune microenvironment: much of our current understanding is derived from studies in animal models.

Optimization and GMP (Good Manufacturing Practices) translation of GLIDE (Guided Lymphocyte Immunopeptide Derived Expansion) manufacturing process

Leukemia, lymphoma and other forms of blood cancers are still largely diagnosed every year in Canada. These diseases constitute the second leading cause of cancer related death in young adults and the sixth in adult. The five-year survival rates still range between 42% and 85%. Currently, the main treatment is a stem cell transplantation which unfortunately do not prevent lethal relapse. The goal of this study is to develop and improve a novel cellular therapy aiming to limit and prevent relapse of hematological malignancies.

Crystallization and mechanism of action studies of antibody NB0940 binding to Poliovirus receptor

Significant advances in technologies related to antibody discovery and development have allowed therapeutic antibodies to become the fastest growing class of biopharmaceuticals over the last 20 years. Northern Biologics is a biotechnology company that seeks to develop therapeutic antibodies for the treatment of cancer and fibrosis. Together with Dr. Jean-Philippe Julien at SickKids (University of Toronto), the intern will work with Northern Biologics to develop and characterize antibodies against cellular receptors that show aberrant signaling in several diseases including cancer.

The Semaphorins, a role Inflammatory Bowel Diseases

Inflammatory bowel disease (IBD) includes both Crohn’s disease (CD), and ulcerative colitis (UC). Approximately 230,000 Canadians are affected by these diseases and they have important repercussions on quality of life and on both personal and societal direct and indirect costs. The cause(s) are poorly understood, and treatment is largely symptom-based and not curative. Commonly used drugs may have potentially important adverse effects such as cancer and serious infections. Moreover, some patients are resistant to these drugs. Therefore, safer and more efficient therapies are needed.

Potential clinical uses of glycopeptides

Red blood cells are stored in blood collection centres for blood transfusion; however, some of red blood cells are discarded due to the poor quality after storage for a period of time because the poor quality of the red blood cells will cause health problems in individuals after transfusion. In this project, we are going to test new compounds derived from natural anti-freezing proteins by a Canada-based biotech company Sirona for better storage of red blood cells. Hopefully, we will find that these new compounds can improve the quality of the red blood cells after storage.

Molecular mechanism of action of anti-fibrotic antibodies

Significant advances in technologies related to antibody discovery and development have allowed therapeutic antibodies to become the fastest growing class of biopharmaceuticals over the last 20 years. Northern Biologics is a biotechnology company that seeks to develop therapeutic antibodies for the treatment of cancer and fibrosis. Together with Dr.

Ingénierie de la lipase B de Candida antarctica pour l'estérification d'acides aromatiques encombrants

Les esters à chaînes courtes sont des molécules employées comme ingrédients de base dans la fabrication d'arômes et de fragrances. Certains esters sont très prisés, tels que ceux entrant dans la composition des arômes de menthe givrée et de fraise. Cependant, ces esters sont particulièrement difficiles à obtenir naturellement et/ou artificiellement. De plus, la demande commerciale est grande pour obtenir ces esters avec une certification naturelle. Il est néanmoins possible de les fabriquer ''naturellement'' en utilisant des enzymes en laboratoire.

Pages